Rockwell Medical Inc (RMTI) Stock AnalysisRMTIRockwell Medical Inc

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rockwell Medical Inc (RMTI) is currently trading at $6.91, which is significantly below its 52-week high of $12.90, indicating potential upside. However, the stock has a low RSI of 34.69, suggesting it is oversold, but also reflects a bearish trend. The forward P/E ratio is 19.53, indicating that the stock may be overvalued based on future earnings expectations. The main risk is the company's negative net income, which was -$1.32 million in Q2 2026, highlighting ongoing financial challenges.

3 analysts cover RMTI: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 3.75.